Search results
Results from the WOW.Com Content Network
Its current director is Dr. Richard Woychik, who is also concurrently the director of the National Toxicology Program. [12] The deputy director is Dr. Trevor Archer. The director of the NIEHS reports to the director of the NIH, of which the NIEHS is a member agency. [13] NIEHS is composed of:
ntp.niehs.nih.gov The National Toxicology Program ( NTP ) is an inter-agency program run by the United States Department of Health and Human Services to coordinate, evaluate, and report on toxicology within public agencies.
Our review found that during fiscal years 2007 through 2009, NIH's National Institute on Drug Abuse (NIDA) did not comply with the time and amount requirements specified in appropriations statutes in administering contract HHSN271-2007-00009C (the Contract) with Charles River Laboratories, Inc.
The NIH Office of Science Policy works on a wide range of issues including biosafety, [2] biosecurity, [3] genetic testing, genomic data sharing, [4] human subjects protections, [5] the organization and management of the NIH, and the outputs and value of NIH-funded research. This is accomplished through a wide range of analyses and reports ...
Pharmacovigilance (PV, or PhV), also known as drug safety, is the pharmaceutical science relating to the "collection, detection, assessment, monitoring, and prevention" of adverse effects with pharmaceutical products.
Nearly half of all 3,100 counties in America have no doctors certified to prescribe buprenorphine by the Substance Abuse and Mental Health Services Administration and the Drug Enforcement Administration, according to a Huffington Post analysis. Hundreds of counties have very few certified doctors.
It amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding market exclusivity for pediatric drug studies on new or already approved drugs, including to change the definition of "pediatric studies" to authorize the Secretary to include preclinical studies, to require the studies to be completed using appropriate ...
In vitro safety pharmacology studies are focused on early hazard identification and subsequent compound profiling in order to guide preclinical in vivo safety and toxicity studies. Early compound profiling can flag for receptor-, enzyme-, transporter-, and ion channel-related liabilities of NCEs (e.g., inhibition of the human ether-a-go-go ...